SI-BONE (SI-BONE) FCF Margin % : -8.72% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is SI-BONE FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SI-BONE's Free Cash Flow for the three months ended in Dec. 2023 was $-3.4 Mil. SI-BONE's Revenue for the three months ended in Dec. 2023 was $38.9 Mil. Therefore, SI-BONE's FCF Margin % for the quarter that ended in Dec. 2023 was -8.72%.

As of today, SI-BONE's current FCF Yield % is -4.43%.

The historical rank and industry rank for SI-BONE's FCF Margin % or its related term are showing as below:

SIBN' s FCF Margin % Range Over the Past 10 Years
Min: -50.94 Med: -43.06 Max: -19.09
Current: -19.09

During the past 8 years, the highest FCF Margin % of SI-BONE was -19.09%. The lowest was -50.94%. And the median was -43.06%.

SIBN's FCF Margin % is ranked worse than
59.95% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.14 vs SIBN: -19.09

SI-BONE FCF Margin % Historical Data

The historical data trend for SI-BONE's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE FCF Margin % Chart

SI-BONE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-50.63

-45.27

-50.94

-48.08

-19.09

SI-BONE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-26.40	-40.76	-18.93	-10.25	-8.72

Competitive Comparison of SI-BONE's FCF Margin %

For the Medical Devices subindustry, SI-BONE's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SI-BONE's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SI-BONE's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SI-BONE's FCF Margin % falls into.

SI-BONE FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SI-BONE's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-26.512	/	138.886
	=	-19.09 %

SI-BONE's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.39	/	38.859
	=	-8.72 %

SI-BONE FCF Margin % Related Terms

Thank you for viewing the detailed overview of SI-BONE's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SI-BONE (SI-BONE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050

Website

http://www.si-bone.com

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Executives

Anshul Maheshwari	officer: Chief Financial Officer	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero	officer: Chief Commercial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn	director, officer: Chairman, President & CEO	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis	officer: Chief Financial Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky	officer: GC & Chief Compliance Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh	director	471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp	10 percent owner	525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling	officer: CMO and VP, Medical Affairs	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby	officer: Chief Technology Officer	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan	director	452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451